newsfilter
← Latest News
GlobeNewswire·

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1